Albany Molecular Research, Inc. Completes Acquisition of Great Lakes Chemical Corporation facility.Business Editors, Health/Medical Writers ALBANY, New York--(BUSINESS WIRE)--Sept. 25, 2001 Albany Molecular Research, Inc. (Nasdaq:AMRI AMRI Albany Molecular Research (stock symbol) AMRI Advanced Magnetic Research Institute (Mocksville, NC) AMRI Advanced Materials Research Institute AMRI Adult Movie Review Index ) announced today that it has successfully completed the purchase of Great Lakes Great Lakes, group of five freshwater lakes, central North America, creating a natural border between the United States and Canada and forming the largest body of freshwater in the world, with a combined surface area of c.95,000 sq mi (246,050 sq km). Chemical Corporation's (NYSE NYSE See: New York Stock Exchange :GLK GLK Glucokinase ) laboratory facilities in Mt. Prospect, Illinois. AMRI first announced the signing of a definitive agreement to purchase the facility on Friday, September 21, 2001. AMRI acquired the 88,000 square foot facility near Chicago, IL for $10 million in cash. Albany Molecular Research, Inc. is a chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential prescription drug applications. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve risks and uncertainties. The company's actual results may differ materially from such forward-looking statements. Factors that could cause such differences include, but are not limited to, the Company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. outsourcing chemical research and development, the Company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the Company's ability to efficiently utilize the Mt. Prospect facility, the ability of the Company's strategic investments to perform as expected, the Company's ability to successfully complete its ongoing expansion projects on schedule, and the Company's ability to effectively manage its growth, as well as those factors discussed in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 as filed with the Securities and Exchange Commission on April 2, 2001 and the company's other SEC filings. The Company does not undertake or intend to update any forward-looking statements contained in this press release after the date of this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion